CEimpact Podcast
The CEimpact Podcast features two shows:
GameChangers Clinical Updates
Precept2Practice
GameChangers Clinical Update Series:
The GameChangers podcast, hosted by Rachel Maynard, PharmD, features the latest game-changing pharmacotherapy advances impacting patient care. New episodes arrive every Monday. Listeners can purchase the episode to earn CE credit at: https://www.ceimpact.com/resources/podcast/
Precept2Practice
The Precept2Practice podcast, hosted by Kathy Schott, brings you tools to mentor students and residents with confidence. New episodes arrive on the third Wednesday of every month. Preceptor By Design™ subscribers can earn CE credit for each episode.
Give us a follow, tune in regularly, and turn your drive time, coffee break, or chart review into a chance to level up your practice. CEimpact continuing education makes pharmacy learning inspiring!
Check back each week for our latest episodes.
CEimpact Podcast
Can Money Buy Health in Heart Failure?
A new study evaluates the cost-effectiveness of dapagliflozin in heart failure. Geoff and Jake continue the conversation from "Home Sweet Home (It's Where the Heart Is)" [Previous Episode] about the role of SGLT-2is in heart failure. This time the conversation is focused on the cost-effectiveness and QALYs. Is the price right for improved care?
Redeem your CPE or CME credit here!
We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964
References and resources:
Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. Published online May 26, 2021. doi:10.1001/jamacardio.2021.1437
Continuing Education Information:
Learning Objectives:
1. Define QALY
2. Discuss the cost-effectiveness of dapagliflozin in heart failure
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-264-H01-P
Initial release date: 7/20/21
Expiration date: 7/20/2022
Complete CPE & CME details can be found here.